TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex® Grant

Provided By PR Newswire

Last update: Nov 12, 2024

EDINBURGH, Scotland, Nov. 12, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has been awarded non-dilutive funding of $250,000 from the G-Rex^® Grant Program.